Last updated: 31 July 2024 at 5:18pm EST

Dr. Cyrus L. Harmon Ph.D. Net Worth




The estimated Net Worth of Cyrus Harmon is at least $15.2 Million dollars as of 29 July 2024. Dr Harmon owns over 5,000 units of Olema Pharmaceuticals stock worth over $9,270,832 and over the last 4 years he sold OLMA stock worth over $5,271,879. In addition, he makes $657,991 as CTO & Director at Olema Pharmaceuticals.

Dr D OLMA stock SEC Form 4 insiders trading

Dr has made over 24 trades of the Olema Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of OLMA stock worth $77,850 on 29 July 2024.

The largest trade he's ever made was selling 30,000 units of Olema Pharmaceuticals stock on 31 January 2024 worth over $383,700. On average, Dr trades about 13,227 units every 39 days since 2020. As of 29 July 2024 he still owns at least 751,283 units of Olema Pharmaceuticals stock.

You can see the complete history of Dr Harmon stock trades at the bottom of the page.





Dr. Cyrus L. Harmon Ph.D. biography

Dr. Cyrus L. Harmon Ph.D. is the CTO & Director at Olema Pharmaceuticals.

What is the salary of Dr D?

As the CTO & Director of Olema Pharmaceuticals, the total compensation of Dr D at Olema Pharmaceuticals is $657,991. There are 1 executives at Olema Pharmaceuticals getting paid more, with Dr. Sean P. Bohen M.D., Ph.D. having the highest compensation of $999,300.



How old is Dr D?

Dr D is 50, he's been the CTO & Director of Olema Pharmaceuticals since . There are 5 older and 3 younger executives at Olema Pharmaceuticals. The oldest executive at Olema Pharmaceuticals, Inc. is Dr. Peter J. Kushner Ph.D., 82, who is the Chief Scientific Officer.

What's Dr D's mailing address?

Cyrus's mailing address filed with the SEC is C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO, CA, 94103.

Insiders trading at Olema Pharmaceuticals

Over the last 4 years, insiders at Olema Pharmaceuticals have traded over $60,548,717 worth of Olema Pharmaceuticals stock and bought 5,935,941 units worth $82,289,865 . The most active insiders traders include Partners L P/Ilbiotechnolog..., G. Walmsley Graham, and Biocapital Advisors Lp Para.... On average, Olema Pharmaceuticals executives and independent directors trade stock every 21 days with the average trade being worth of $1,893,968. The most recent stock trade was executed by Biocapital Advisors Lp Para... on 1 August 2024, trading 2,400,000 units of OLMA stock currently worth $35,808,000.



What does Olema Pharmaceuticals do?

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.



What does Olema Pharmaceuticals's logo look like?

Olema Pharmaceuticals, Inc. logo

Complete history of Dr Harmon stock trades at Olema Pharmaceuticals

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
29 Jul 2024 Cyrus Harmon
Sale 5,000 $15.57 $77,850
29 Jul 2024
751,283
11 Jul 2024 Cyrus Harmon
Sale 5,000 $12.26 $61,300
11 Jul 2024
756,283
28 Jun 2024 Cyrus Harmon
Sale 20,000 $10.77 $215,400
28 Jun 2024
761,283
31 May 2024 Cyrus Harmon
Sale 25,000 $10.30 $257,500
31 May 2024
781,283
6 May 2024 Cyrus Harmon
Sale 5,000 $10.92 $54,600
6 May 2024
806,283
30 Apr 2024 Cyrus Harmon
Sale 15,000 $9.51 $142,650
30 Apr 2024
811,283
28 Mar 2024 Cyrus Harmon
Sale 20,000 $10.97 $219,400
28 Mar 2024
826,283
29 Feb 2024 Cyrus Harmon
Sale 25,000 $12.41 $310,250
29 Feb 2024
846,283
31 Jan 2024 Cyrus Harmon
Sale 30,000 $12.79 $383,700
31 Jan 2024
871,283
29 Dec 2023 Cyrus Harmon
Sale 25,000 $13.38 $334,500
29 Dec 2023
901,283
30 Nov 2023 Cyrus Harmon
Sale 25,000 $12.57 $314,250
30 Nov 2023
926,283
20 Nov 2023 Cyrus Harmon
Sale 8,181 $14.39 $117,725
20 Nov 2023
951,283
31 Oct 2023 Cyrus Harmon
Sale 30,000 $12.65 $379,500
31 Oct 2023
943,714
29 Sep 2023 Cyrus Harmon
Sale 25,000 $12.41 $310,250
29 Sep 2023
973,714
31 Aug 2023 Cyrus Harmon
Sale 25,000 $10.26 $256,500
31 Aug 2023
998,714
16 Aug 2023 Cyrus Harmon
Sale 15,000 $10.14 $152,100
16 Aug 2023
1,023,714
8 Jun 2023 Cyrus Harmon
Sale 10,000 $6.30 $63,000
8 Jun 2023
1,038,714
5 Jun 2023 Cyrus Harmon
Sale 10,000 $6.17 $61,700
5 Jun 2023
1,048,714
29 Nov 2021 Cyrus Harmon
Sale 400 $24.76 $9,904
29 Nov 2021
1,051,146
19 Oct 2021 Cyrus Harmon
Sale 12,000 $27.98 $335,760
19 Oct 2021
1,051,546
20 Sep 2021 Cyrus Harmon
Sale 12,000 $26.30 $315,600
20 Sep 2021
1,063,546
19 Aug 2021 Cyrus Harmon
Sale 12,000 $24.97 $299,640
19 Aug 2021
1,075,546
20 Jul 2021 Cyrus Harmon
Sale 12,000 $25.10 $301,200
20 Jul 2021
1,087,546
18 Jun 2021 Cyrus Harmon
Sale 12,000 $24.80 $297,600
18 Jun 2021
1,099,546


Olema Pharmaceuticals executives and stock owners

Olema Pharmaceuticals executives and other stock owners filed with the SEC include: